The terms of the transaction were not disclosed, but both Citi and Occidental said the purchase price was equal to the approximate net asset value of the business. Occidental estimated its net investment in Phibro at about $250 million. The sale is expected to close in the fourth quarter.
Citi said the decision to sell Phibro was the outcome of an evaluation of a variety of alternatives and is consistent with Citi's core strategy of a client-centred business model. It also claimed the sale would
The week on Risk.net, October 6-12, 2017Receive this by email
- Quantile, TriOptima face off in cleared swaps compression battle
- ABS set for revival under US Treasury’s liquidity buffer plans
- Leaked EU doc could shield legacy swaps from clearing grab
- Industry hails potential US relaxation of margin timing rules
- SGX, HKEX expect to be among first wave of Mifid II equivalence